Syncona (LSE:SYNC) Common Stock : £757.12 Mil (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Syncona Common Stock?

Syncona's quarterly common stock increased from Sep. 2022 (£757.28 Mil) to Mar. 2023 (£783.77 Mil) but then declined from Mar. 2023 (£783.77 Mil) to Sep. 2023 (£757.12 Mil).

Syncona's annual common stock declined from Mar. 2020 (£767.61 Mil) to Mar. 2021 (£761.11 Mil) but then increased from Mar. 2021 (£761.11 Mil) to Mar. 2022 (£765.71 Mil).

Syncona Common Stock Historical Data

The historical data trend for Syncona's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncona Common Stock Chart

Syncona Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Common Stock

Get a 7-Day Free Trial

765.67

758.34

767.61

761.11

765.71

Syncona Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Common Stock	Get a 7-Day Free Trial															750.71	765.71	757.28	783.77	757.12

Syncona Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Syncona (LSE:SYNC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Syncona Ltd (LSE:SYNC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SYNCl:UK

Address

8 Bloomsbury Street, 2nd Floor, London, GBR, WC1B 3SR

Website

https://www.synconaltd.com

Syncona Ltd is a closed-ended investment company in the United Kingdom. Its investment objective is to achieve superior long-term capital appreciation from its investments. The company invests in life science businesses (including private and quoted companies) and single or multi-asset projects (Life Science Investments).